28 results about "Animals vaccines" patented technology

This utility model relates to the field of medical equipment technology, and in particular to an animal vaccine injection booster device, comprising a first air chamber, a second air chamber, a piston assembly, and a gun body; the gun body has a first air chamber and a second air chamber, the first air chamber having a gas source inlet, a gas outlet, and a gas delivery outlet, the gas delivery outlet communicating with the second air chamber, and a control valve also being provided in the first air chamber; when the trigger of the gun body presses the control valve, the control valve blocks the connection between the gas delivery outlet and the gas outlet; when the trigger of the gun body is released, the control valve blocks the connection between the gas delivery outlet and the gas source inlet; the second air chamber has a piston assembly, the piston assembly including a piston and a firing pin, the firing pin being disposed on the piston, and an elastic element being provided between the piston and the firing pin output end of the second air chamber; the trigger is disposed on the grip part of the gun body, the grip part having a grip groove on the side near the trigger, and a thumb groove on the top side of the grip part away from the trigger. This utility model is easy to operate and has a good grip feel.

1. Name of the product in this design: Animal vaccination station (for veterinary use). 2. Purpose of this design: For vaccinating animals. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application relates to the technical field of biological medicine, and particularly discloses CpG oligodeoxynucleotides and application thereof. The CpG oligodeoxynucleotide has a sequence as shown in any one of SEQ ID NO. 3-6, 9, and preferably has a sequence as shown in SEQ ID NO. 3-6. The CpG oligodeoxynucleotide can effectively activate the immune system of a human body or an animal, has the functions of preventing and treating pathogenic microorganism infection in a broad spectrum, has the function of improving the immunogenicity of a common vaccine, and can be applied as a human or animal vaccine adjuvant.

The invention discloses a bovine virus diarrhea live vaccine based on suspension culture and a preparation method thereof, and relates to the field of animal vaccines. The bovine viral diarrhea virus vaccine is a freeze-dried vaccine, and each vaccine contains a bovine viral diarrhea virus BVDV attenuated strain antigen and a freeze-drying protective agent; wherein the virus content of the antigen of the BVDV attenuated strain is 105-107 CCID50 / piece, and the BVDV attenuated strain is a cytopathic effect type attenuated strain suitable for suspension culture; the freeze-drying protective agent comprises trehalose, cane sugar, gelatin hydrolysate, sodium glutamate and polyvinylpyrrolidone. The suspension culture technology is adopted, large-scale, efficient and stable production of BVDV antigens is achieved, an optimized freeze-drying formula is combined, the obtained vaccine is high in virus titer, good in immunogenicity, high in stability, good in safety, advanced in production process, controllable in cost and suitable for industrial large-scale production.

The application belongs to the technical field of animal vaccines, and particularly relates to an O-A-Dex-Ap for African swine fever immunization. Based on the good biocompatibility of Dextran, the application uses the Dextran as a nanoparticle to load a coupled CTL epitope peptide. Preliminary experimental results show that, compared with the epitope peptide alone, the O-A-Dex-Ap after loading and coupling can more effectively promote antigen presentation and activate more persistent CTL immune response, and has good application potential. Based on the results, a good technical foundation can be laid for subsequent preparation of African swine fever and other disease vaccines.

The invention discloses application of CpG ODN in preparation of a medicine for regulating animal immune cell activity, and relates to the technical field of animal vaccines. In the invention, the regulation of the animal immune cell activity is to promote the immune response reaction of immune cells; the step of promoting the immune response reaction of the immune cells comprises the step of promoting the immune cells to generate interferon. The CpG ODN provided by the invention can well and specifically stimulate immune cells of animals, especially pigs to release cytokines and promote the animals to generate rapid and strong immune response to immunogens; when being applied to an animal vaccine, the vaccine can stimulate animals to generate a higher antibody level in a shorter time, and can maintain the high-level antibody for a long time, and the immunogenicity of the vaccine is remarkably improved.

The utility model relates to the technical field of animal medical treatment, and discloses an angle-adjustable animal vaccine injection auxiliary device which comprises a bottom plate and an upper plate, the upper plate is arranged right above the bottom plate, a sleeve is fixed above the bottom plate, a supporting rod is arranged in the sleeve in a sliding mode, one end of the supporting rod penetrates through the sleeve and is connected to the bottom of the upper plate in a rotating mode, and the other end of the supporting rod is connected to the lower portion of the upper plate. A limiting mechanism is arranged between the supporting rod and the sleeve, an adjusting mechanism is connected between one side of the upper portion of the supporting rod and the upper plate, and a clamping mechanism is arranged above the upper plate. An operator firstly places the device at a proper position close to an animal to be injected, and the height of the device can be adjusted by adjusting the height of the supporting rod, so that the height of the device can be adjusted according to rough heights of animals with different heights and different parts.

The invention discloses a recombinant duck enteritis virus for expressing 3-type duck hepatitis A virus immunogenic genes and a construction method and application thereof. The recombinant duck enteritis virus is characterized in that an eukaryotic expression cassette containing a type 3 duck hepatitis A virus immunogenic gene is inserted into a non-coding region between UL26 and USL27 genes of a duck enteritis virus genome. According to the invention, a duck hepatitis A virus (DHAV) immunogenic gene is inserted into a duck enteritis virus (DEV) genome at a fixed point by virtue of a CRISPR / Cas9 gene editing technology, so that the recombinant duck enteritis virus for expressing the duck hepatitis A virus type 3 immunogenic gene is constructed and obtained. Moreover, based on the recombinant duck enteritis virus for expressing the 3-type duck hepatitis A virus immunogenicity gene constructed by the invention, the exogenous DHAV immunogenicity gene can be stably expressed in the recombinant virus, and the recombinant virus has good in-vitro replication ability and hereditary stability and can be used for preparing animal vaccines.

The invention discloses a bovine virus diarrhea and rhinotracheitis bivalent inactivated vaccine and a preparation method thereof, and relates to the field of animal vaccines. The composition is prepared from the following components in parts by volume: 40-50 parts of a water phase and 50-60 parts of an oil phase, the water phase comprises a bovine viral diarrhea virus antigen solution, an infectious bovine rhinotracheitis virus antigen solution, a stabilizer, a preservative and a phosphate buffer solution; the oil phase is prepared from white oil, span-80 and tween-80. The invention adopts BPL to inactivate BVDV and formaldehyde to inactivate IBRV, the inactivation process is designed according to virus characteristics, the inactivation is thorough, the safety is high, the immunogenicity of the virus can be retained to the greatest extent, the vaccine formula is scientific, and the physical and chemical stability of the vaccine during the storage period is improved by adopting the compound stabilizer.

The utility model relates to the field of animal vaccine immunization, in particular to a portable vaccine dilution operation table which comprises a sealing bin, a transparent partition plate fixedly installed at the upper end of the sealing bin, a sealing door arranged on the front side of the sealing bin, a sealing operation glove arranged on the inner side of the sealing bin and an operation platform arranged at the lower end of the sealing bin. Self-locking universal wheels are arranged at the lower end of the operating platform, a vertical plate is arranged at the upper end of the operating platform, an illuminating lamp is fixedly installed on the front side of the vertical plate, a sprayer is arranged below the illuminating lamp, a disinfectant box is arranged on the rear side of the vertical plate, a filter box is arranged at the upper end of the rear side of the vertical plate, and a sealing cover is arranged on the rear side of the filter box. According to the utility model, the sealed operation glove is used for operation in the sealed bin, potential biological safety hazards such as vaccine spilling and aerosol diffusion are effectively avoided, and the biological safety risk is further reduced by spraying and disinfecting articles in the sealed bin through the sprayer, ventilating the sealed bin through the fan and filtering airflow through the filter element.

The invention belongs to the technical field of animal breeding, and particularly relates to an animal vaccination device which comprises a medicine box, a positioning frame is fixed to the bottom end of the medicine box, a medicine pumping pipe is arranged in the positioning frame, a needle is mounted at the bottom end of the medicine pumping pipe, a piston is arranged in the medicine pumping pipe, a push rod is fixed to the top end of the piston, and a movable hole is formed in the middle of the medicine box. Fixing plates are fixed to the two sides of the interior of the movable hole, lifting rods are fixed to the two sides of the top end of the pesticide pumping pipe, a lifting plate is fixed to the middles of the lifting rods, first springs are fixed to the top end of the lifting plate, the top ends of the first springs are fixedly connected with the bottom ends of the fixing plates, and a trigger assembly is arranged below the lifting plate; the needle head is positioned through the positioning frame, then the push plate is pressed to drive the clamping plate to be separated from the lifting plate, so that the first spring is released to drive the lifting rod, the lifting rod drives the needle head to be quickly inserted into an animal body, the animal positioning time is shortened, and the inoculation efficiency can be improved.

The application belongs to the technical field of animal vaccine preparation, and discloses an African swine fever virus (ASFV) multi-epitope fusion protein, a ferritin nanoparticle vaccine of the ASFV multi-epitope fusion protein and application. The application obtains 16 dominant B cell epitopes by using an ASFV phage display library in combination with reverse screening of clinical positive serum, and constructs a nanoparticle vaccine by linking the 16 epitopes with ferritin self-assembly. The vaccine has excellent biosafety, can induce high-level and sustained specific antibodies and significant IFN-gamma cellular immune response in pigs, can effectively delay the clinical onset and death process of pigs in ASFV virulent challenge experiments, and can significantly reduce the virus load in whole-body organ tissues, thereby providing 25% survival protection rate. The application provides an effective new strategy for the development of a subunit vaccine for responding to various ASFV mutant strains.

The invention belongs to the technical field of animal vaccine preparation, and discloses an African swine fever virus multi-epitope fusion protein and a ferritin nanoparticle vaccine and application thereof. According to the invention, an ASFV phage display library is combined with clinical positive serum reverse screening to obtain 16 dominant B cell epitopes, and the 16 epitopes are connected in series with an epitope and are self-assembled with ferritin to construct the nanoparticle vaccine. The vaccine has excellent biological safety; a high-level and continuous specific antibody and remarkable IFN-gamma cellular immune response can be induced and generated in a pig body; in an ASFV virulent virus challenge experiment, the vaccine can effectively delay clinical morbidity and death processes of pigs, remarkably reduce virus load in visceral organ tissues of the whole body and provide a survival protection rate of 25%. The invention provides an effective new strategy for research and development of subunit vaccines for coping with ASFV multi-variant strains.

The application provides a kind of composite nano adjuvant preparation based on zirconium metal organic framework and its application in animal vaccine.The nano adjuvant preparation includes zirconium metal organic framework material and one or more polymers, and the mass ratio of the porous zirconium metal organic framework material to the polymer is 1:1-3.The composite nano adjuvant preparation based on zirconium metal organic framework provided by the application has good stability and safety, can effectively enhance immune response and attack protection effect, and can be widely used in the preparation of animal inactivated vaccine, attenuated vaccine, recombinant protein vaccine, polypeptide vaccine and nucleic acid vaccine.The composite adjuvant preparation has low cost, simple preparation process and easy scale production.

Animal vaccine spraying equipment comprises a conveying mechanism, a liquid medicine box and a spraying mechanism, a belt type conveying mechanism comprises a transmission device and a conveying belt, a plurality of limiting clamping plate sets are arranged on the conveying belt in the moving direction of the conveying belt, each limiting clamping plate set comprises three limiting clamping plates arranged at different intervals, and the limiting clamping plates are arranged on the conveying belt. Wherein the first distance between every two adjacent limiting clamping plates is equal to the length of the baby chick frame, and the second distance is smaller than the length of the baby chick frame; the two groups of spraying mechanisms are respectively communicated with two ports of the liquid medicine box and are arranged on the two sides of the conveying belt in a staggered manner; the liquid medicine box is arranged at one end of the conveying mechanism, and a stirring device is arranged in the liquid medicine box. Each baby chick frame can be fully immunized, the immunization efficiency is improved, the device has an easy backup function, and the loss caused by shutdown maintenance of the device is reduced.

1. The name of the design product: continuous syringe. 2. The use of the design product: continuous injection for animal vaccine. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.

The invention relates to an application of an activity regulating cytoskeleton associated protein (ARC) in an REV nanoparticle vaccine and the vaccine, and belongs to the technical field of animal vaccine preparation, the amino acid sequence of the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3, the nucleotide sequence is shown as SEQ ID NO.4, and the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3. The activity regulation cytoskeleton associated protein is used as a carrier protein in a nanoparticle vaccine, and the nanoparticle vaccine is an REV nanoparticle vaccine. The ARC is used as a carrier in the nanoparticle vaccine for the first time to be self-assembled into nanoparticles, and the nanoparticles can serve as an antigen delivery platform, play a protein-antigen delivery role and stimulate an organism to generate immune response.

The invention provides an adjuvant for an oil-in-water animal vaccine. The adjuvant contains 8.8%-19.6% of mineral oil, 3.7%-6.6% of span 80, 6.1%-11.0% of Tween 80, 3.9%-7.0% of glycerol, 2.9%-5.3% of polyglycerol ester and the balance of water for injection, wherein the total percentage of the adjuvant is 100%. The oil-in-water adjuvant disclosed by the invention is simple in formula and simple in preparation method; the animal vaccine prepared by utilizing the adjuvant is good in physical stability, can be stored for more than 12 months at 4 DEG C, can be stored for 12 months at 25 DEG C and can be stored for 2 months at 37 DEG C, and the storage stability is obviously superior to that of similar products at home and abroad; the animal vaccine prepared from the adjuvant is low in viscosity and easy to inject, no visible residue exists in animal experiments, death or obvious adverse reaction caused by vaccine injection is avoided, and guarantee is provided for vaccine injection safety and effectiveness and economic animal food safety.

The invention provides a mucosal immune vaccine based on a porcine parainfluenza virus PIV5 carrier and application of the mucosal immune vaccine in immunization of sows and piglets, and belongs to the technical field of animal vaccines. According to the invention, on the basis of a porcine PIV5 reverse genetic operating system, the S gene of the porcine delta coronavirus (PDCoV) is inserted into a P-M gene spacer region of the PIV5 by using a P-M exogenous gene expression cassette of the PIV5, and a recombinant vaccine capable of expressing the PDCoV S is successfully rescued, and is named as JS17-PDCoV-S. A high-titer neutralizing antibody can be generated after the piglets are immunized by oral administration; after a sow orally takes the JS17-PDCoV-S vaccine, high-level serum IgG and mucous membrane sIgA antibodies can be generated. Meanwhile, the piglets are passively immunized by sucking milk, whole body and mucous membrane immune protection aiming at specific pathogens is provided for the piglets, early infection is effectively prevented, and the problem that IgG is easily degraded by digestive tracts of the piglets is solved.

The invention provides an oral vaccine based on a porcine parainfluenza virus PIV5 carrier as well as a preparation method and application of the oral vaccine, and belongs to the technical field of viral vectors and animal vaccines. According to the invention, pig source PIV5 and monkey source PIV5 are respectively taken as carriers, S protein of porcine delta coronavirus (PDCoV) is taken as an antigen, and monkey source PIV5 recombinant virus and pig source PIV5 recombinant virus for expressing PDCoV-S are respectively constructed. Piglet immunization is carried out in an oral-oral immunization mode, the antibody level after immunization is detected, and the result shows that the level of a neutralizing antibody induced by the pig source PIV5 recombinant virus is higher than that of a monkey source PIV5 recombinant virus. The ELISA (enzyme-linked immunosorbent assay) result proves that the IgG (immunoglobulin G) level mediated by the porcine PIV5 recombinant virus is higher than the IgG level mediated by the monkey PIV5 recombinant virus, which indicates that the PIV5-JS17 strain is more suitable for serving as an exogenous gene delivery system of pigs than the PIV5-W3A strain.

The application provides a water-in-oil adjuvant for poultry animal vaccines and a preparation method and application thereof, and belongs to the technical field of biological product animal vaccines. The raw materials of the water-in-oil adjuvant provided by the application include, in percentage by mass, 85wt%-90wt% of injection oil, 5wt%-10wt% of refined Span-80 and 1wt%-5wt% of refined Tween-80, and can further include 0.1wt%-1wt% of an immune stimulating complex. The vaccine prepared by using the water-in-oil adjuvant provided by the application is stable in quality, high in safety, and can induce the body to produce an immune response with a longer duration and higher efficiency, and therefore can be used as a safe and effective adjuvant for poultry animal vaccines and the like.

The application provides a water-in-oil-in-water adjuvant for livestock vaccines and a preparation method and application thereof, and belongs to the technical field of animal vaccines of biological products. The raw materials of the water-in-oil-in-water adjuvant include, in percentage by mass, 75wt%-85wt% of injection oil, 1wt%-5wt% of refined Span-80 and 10wt%-24wt% of refined Tween-80, and can further include 1wt%-3wt% of an immunostimulating complex. The vaccine prepared by using the water-in-oil-in-water adjuvant provided by the application is stable in quality, high in safety, and can induce the body to produce an immune response with a longer duration and higher efficiency, and therefore can be used as a safe and effective adjuvant for livestock vaccines and the like.

This invention discloses a method for preparing and applying a recombinant porcine deltacoronavirus (PDCoV) S1 protein and subunit vaccine expressed in CHO cells, belonging to the field of animal vaccines and veterinary biological products technology. Its purpose is to provide a method for large-scale industrial production of a recombinant subunit vaccine against porcine deltacoronavirus. The recombinant subunit vaccine preparation method provided by this invention includes the following steps: 1. Cloning a eukaryotic expression vector containing the PDCoV S1 protein encoding gene; 2. Transfecting CHO cells, and obtaining a CHO cell line that stably and efficiently expresses the PDCoV S1 protein in suspension through selection, screening, and domestication; 3. Thoroughly mixing the PDCoV S1 protein with ISA 201 VG to obtain the recombinant subunit vaccine. Animal experiments on piglets show that high levels of neutralizing antibodies are produced 21 days after immunization.

The invention provides a clostridium perfringens QL08 strain, and the preservation number of the clostridium perfringens QL08 strain is CGMCC No.33890. The invention also provides an animal vaccine containing the clostridium perfringens QL08 strain or a culture of the clostridium perfringens QL08 strain, and application of the clostridium perfringens QL08 strain in preparation of the animal vaccine. The invention also provides a toxin-producing culture medium. A type A clostridium perfringens QL08 strains can be fermented and cultured by the aid of the toxin-producing culture medium, fermentation culture time can be only 4-5 hours by optimizing fermentation conditions, toxin content can reach 250-300 mouse MLD / ml, and the toxin-producing culture medium has excellent industrial application value. The components of the culture medium are cheap and easy to obtain, the preparation method of the culture medium is simple, and the quality is stable. The A-type clostridium perfringens toxin vaccine provided by the invention has no adverse reaction when used for immunizing various animals, generates high-level neutralizing antibodies, and is a safe and effective A-type clostridium perfringens toxin general vaccine.

The invention relates to the technical field of animal vaccine preparation, and discloses a sterile filling and plugging machine for preparing animal vaccine.The sterile filling and plugging machine comprises a rack, and a filling piece and a plugging piece are installed on the rack; the conveying assembly comprises a rotating disc and an adjusting part, the rotating disc is rotationally connected to the rack, a plurality of penicillin bottles are stored in the rotating disc, the height of the penicillin bottles is adjusted through the adjusting part, and the filling part and the plugging part are located on the two sides of the rotating disc respectively and used for conducting filling and plugging on the penicillin bottles; the plurality of shielding pieces are arranged on the rotating disc in the circumferential direction, and after the penicillin bottles are filled, the shielding pieces shield the penicillin bottles; and the output assembly comprises a screening piece and an output piece, the output piece is arranged on the rack and used for receiving the penicillin bottles with the plugs, and the screening piece is arranged on the output piece and used for screening the penicillin bottles. The device is small in occupied area, vaccine pollution is avoided, and the vaccine product quality is guaranteed.

The utility model provides a kind of animal vaccine high -efficient injection booster belongs to the field of animal husbandry veterinarian, including needle cylinder, needle, push rod and lug, the needle is communicated and is set on the side wall of needle cylinder, the push rod is slidably connected in the inside of needle cylinder, two The lug is fixedly connected on the outer wall opposite to the end of needle cylinder away from needle, the lower portion of needle cylinder is provided with booster mechanism, drive assembly is provided on the booster mechanism.The utility model is provided with booster mechanism, needle is placed in the container containing vaccine when using, then pull push rod and draw vaccine into needle cylinder inside, then needle cylinder is placed at the top of first arc plate and second arc plate, then move needle cylinder, so that two lugs are inserted into two placing frame inside, and then the needle cylinder is initially fixed, when injection, rotate screw rod, so that push plate pushes push rod to move towards needle, and then play booster effect.

The invention relates to the technical field of animal vaccines, in particular to a multivalent porcine circovirus vaccine. The invention provides a nucleic acid construct. The nucleic acid construct comprises neutralizing antigen epitope coding sequences of PCV2a, PCV2d and PCV2e of porcine circovirus type 2, a PCV2b Cap protein antigen epitope coding sequence, a PCV3a Cap protein antigen epitope coding sequence and a PCV4a Cap protein antigen epitope coding sequence which are sequentially connected in series, amino acid sequences corresponding to the PCV2a neutralizing antigen epitope, the PCV2d neutralizing antigen epitope, the PCV2e neutralizing antigen epitope, the PCV2b Cap protein antigen epitope, the PCV3a Cap protein antigen epitope and the PCV4a Cap protein antigen epitope are respectively and sequentially shown as SEQ ID NO: 1 to SEQ ID NO: 6, and the nucleic acid construct can encode the amino acid sequences so as to be used for expressing the corresponding multi-epitope fusion protein.